For Locally Advanced or Metastatic Urothelial Carcinoma TECENTRIQ: A Legacy of Firsts

Over the past 30 years, no new treatments had been FDA approved for locally advanced or metastatic urothelial carcinoma–until TECENTRIQ 1-5

2016: prior platinum-treated patients gained a treatment option with TECENTRIQ 1,6

  • Prior to 2016, patients who progressed on chemotherapy were left with the option of palliative chemotherapy, clinical trial enrollments, or no treatment

2017: more patients are eligible for treatment with TECENTRIQ 1

  • Cisplatin-ineligible patients are a patient population that previously had few treatment options
    • Many patients may be considered ineligible for cisplatin-based chemotherapy due to 7
      • Renal dysfunction
      • Poor performance status
      • Other comorbidities 

Cisplatin-ineligible patients should be selected for PD-L1 expression (PD-L1–stained tumor-infiltrating immune cells [IC] covering ≥5% of the tumor area) via FDA-approved test.